Innovation’s Kevetrin Shows Promising Results in Trial for Late-stage Ovarian Cancer

Innovation’s Kevetrin Shows Promising Results in Trial for Late-stage Ovarian Cancer
A Phase 2a trial testing Innovation Pharmaceuticals’ p53 modulator Kevetrin as a treatment for late-stage ovarian cancer has been completed, the company announced. The study showed positive anti-cancer results, supporting the development of an oral formulation of the investigational therapy. Kevetrin is a small-molecule activator of p53, a key protein across human cancer. The p53 gene is a tumor

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *